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In the present study, the effect of orexin-A (ORXA) microinjection into the paragiganto-
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thermal and chemical models of pain in rat, was examined. Also, we determined whether
the pretreatment with SB-334867, a selective OX1-receptor antagonist, would prevent the
antinociceptive effect of orexin-A. ORXA (0.1–100 nM/0.5 mL) microinjected into the LPGi
nucleus, dose-dependently decreased the formalin induced nociceptive behaviors and also
produced a dose-dependent antinociceptive effect in the hot-plate test. Pretreatment with
a selective orexin receptor 1 (OX1R) antagonist, SB-334867, also inhibited the effect of
ORXA on formalin induced nociceptive behaviors while the SB-334867 (100 mM) alone had
no effect on formalin test. These data demonstrated that the ORXA-induced antinocicep-
tion in formalin test is mainly mediated through the OX1R in LPGi which might play a
potential role in processing the pain information associated with descending pain
modulation.
& 2012 Elsevier B.V. All rights reserved.1. Introduction
Orexin-A (ORXA, a cyclic 33-amino acid peptide also known
as hypocretin-1) and orexin-B (ORXB, or hypocretin-2, a
linear, 28-amino acid peptide) are produced from the pre-
cursor protein prepro-orexin in neurons and restricted to a
few regions of the lateral hypothalamus (LH) (Peyron et al.,
1998; Sakurai et al., 1998). ORXA and ORXB activate the two
G-protein coupled receptors, orexin 1 receptor (OX1R) and
orexin 2 receptor (OX2R) (Sakurai et al., 1998). Several lines ofr B.V. All rights reserved.
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ular Research Center, Qazv
m (H. Azhdari-Zarmehri)evidence imply that the orexin is involved in reward, addic-
tion (Aston-Jones et al., 2009, 2010; Harris et al., 2005), and
nociceptive sensory processes (Azhdari Zarmehri et al., 2008,
2011; Bingham et al., 2001; Mobarakeh et al., 2005; Yamamoto
et al., 2002). ICV injection of ORXA (hypocretin-1) has been
shown to elicit analgesic responses processes (Bingham et al.,
2001; Mobarakeh et al., 2005; Yamamoto et al., 2002) and
OX1R is involved in responsiveness to both pain and stressful
stimuli (Sofi-Abadi et al., 2011; Watanabe et al., 2005).
However, the locations of central sites that may mediatein University of Medical Sciences, Qazvin, Iran. Fax:þ98 281 3336005.
.
Fig. 1 – Location of injections as percentage of maximum
possible effect (%MPE) on the LPGi nucleus: black square for
0–10%, black circle for 10–25%, white circle for 25–50%, black
triangle for 50–75%, and white triangle for over 75% effect.
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receptors and orexinergic projections are localized in regions
previously shown to play a role in pain modulation such as
periaqueductal gray (PAG), locus coeruleus, and paragiganto-
cellularis lateralis (LPGI) (Mondal et al., 1999; Peyron et al.,
1998). The LPGi in the medulla is implicated in several
functions including cardiovascular control, respiration, pain,
and analgesia (Van Bockstaele et al., 1989; Van Bockstaele and
ston-Jones, 1995; Zhou et al., 1993, 1995. Furthermore, the LH
appears to modify nociception, in part, through the brain
stem (Behbehani et al., 1988; Holden and Pizzi, 2008) and
there are even several studies in which the interaction of LH
with LPGi is documented (Andrezik et al., 1981; Li and Lovick,
1985). Nevertheless, the role of ORXA within LPGI in pain
control has not been determined yet. In our previous study,
we have shown that the ORXA has a moderate effect on PAG
in formalin induced nociceptive behaviors (Azhdari Zarmehri
et al., 2011). There is widespread projections of orexinergic
pathway and orexin receptors expression in LPGI (Ciriello
et al., 2003; Mondal et al., 1999; Peyron et al., 1998). Therefore,
in this study, the effect of ORXA microinjection into LPGI on
formalin induced nociceptive behaviors and hot-plate test
was investigated. To further verify the role of OX1Rs in the
LPGi, the effect of the selective OX1R antagonist on antino-
ciceptive effect of ORXA was also examined in formalin test.
The plane is modified to a series of three sections for the
brain area from the atlas of Paxinos and Watson (The Rat
Brain in Stereotaxic Coordinates, fourth ed. Academic Press,
New York; Paxinos and Watson, 2005) the approximate
coordinate indicated is in millimeters posterior to the
bregma (data shown are only from 100 nM ORXA in
formalin test).2. Results
2.1. Intra-LPGi application of ORXA decreased formalin-
induced nociceptive behaviors
Formalin injection into the plantar surface of the right hind
paw produced typical biphasic nociceptive responses (Abbott
et al., 1995; Dubuisson and Dennis, 1977). The first and
second phases were separated by a brief inter-phase where
the nociceptive behaviors were sporadically observed in the
vehicle group. The columns represent the mean nociceptive
score at each phase: phase 1 (minutes 1–7), inter-phase
(minutes 8–14), and phase 2 (minutes 15–60) for all figures.
Only those rats with microinjection site and diffusion located
within the nucleus were included in the results (Fig. 1, data
from 100 nM orexin-A are shown). To determine the appro-
priate dose of ORXA for microinjection into the LPGi and
showing the antinociceptive effect in formalin test, the
orexin microinjection into the LPGi started from 0.1 nM
concentration (Fig. 2C). In part B of the figure, the average
pain scores of different doses of ORXA 0.1 nM (n¼4), 0.0.5 nM
(n¼5), 10 nM (n¼4), 50 nM (n¼6), and 100 nM in 0.5 ml at
different phases of formalin test is shown. The antinocicep-
tive effect of ORXA was observed from 10 nM in phase 1 and
1 nM in phase 2 of the formalin test. Intra-LPGi microinjec-
tion of 10, 50, and 100 nM of ORXA caused a decrease in
formalin-induced nociceptive behaviors in phase 1 as com-
pared to saline-treated rats (Fig. 2C, Po0.05 by ANOVA), and
the effect was dose-dependent. Similarly, the intra-LPGi
microinjection of ORXA (1, 10, 50, and 100 nM) also caused a
decrease in formalin-induced nociceptive behaviors in phase
2 as compared to saline-treated rats (Fig. 2C, Po0.05 by
ANOVA), and again the effect occurred in a dose-dependentmanner (Fig. 2C). To compare the antinociceptive effects of
ORXA with morphine, the latter was microinjected (50 nM/
0.5 ml, n¼6) into the LPGi and the outcome was a vigorous
decrease in formalin-induced nociceptive behaviors in phase
1, inter-phase, as well as the phase 2 of the formalin test
(Fig. 2A and B). The antinociceptive effect of intra-LPGi
injection of ORXA (100 nM) was similar to that of morphine
in the formalin test. All microinjections were made into the
right side of the LPGi and the results presented here only
include the animals for which the confinement of injection to
the LPGi region was confirmed and the data from all dubious
injections were rejected. When the peptide was microinjected
into the reticular formation surrounding the LPGi, it failed to
produce any obvious effect on formalin induced nociceptive
behaviors, indicating that the site for peptide action was
within the LPGi rather than the adjacent medullary reticular
formation.
2.2. Effects of ORXA injection into the LPGi nucleus on
hot-plate test
According to the formalin test experiments, after LPGi micro-
injection of ORXA, different doses of ORXA (1–100 nM), to
compare the antinociceptive effect of this drug on hot-plate
test, was also administered. Intra-LPGi microinjection of ORXA
at 50 and 100 nM concentrations significantly increased the
latency in the hot-plate test at 15 (Po0.01), 30 (Po0.01) and 60
Fig. 2 – Time course of formalin-induced nociceptive behaviors score (7S.E.M.) following intra-LPGi infusion of ORXA (100 nM
in 0.5 ll, n¼7) and morphine, measured every 3 min for 60 min (A). Bar chart shows the average pain scores of ORXA (100 nM
in 0.5 ll) and morphine at each phase of the formalin test (B). Average pain scores of different doses of ORXA 0.1 nM (n¼4),
0.0.5 nM (n¼5), 10 nM (n¼4), 50 nM (n¼6), and 100 nM in 0.5 ll) at different phases of formalin test (C). For clarity, only ORXA
(100 nM) and morphine (50 nM, n¼6)) is plotted in separate graphs, with the same vehicle group. nPo0.05; nnPo0.01;
nnnPo0.001 in comparison with saline (the number of animals for different doses of orexin 0.1, 0.5, 10 and 50 nM was 6).
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minutes following drug administration (Fig. 3). Similarly, the
microinjection of ORXA at 10 nM (n¼6) concentration signifi-
cantly increased the latency in the hot-plate test at 15 (Po0.05),
30 (Po0.05) and 60 (Po0.05) minutes after administration of
drug (Fig. 3). However, the microinjection of ORXA at 1 nM
concentration (n¼6) only caused an increase in latency follow-
ing hot-plate test at 15 (Po0.05) and 30 (Po0.05) minutes after
drug administration (Fig. 3) but not at 60 min.
2.3. Effects of SB-334867 (OX1R antagonist)
microinjection into the LPGi on ORXA-induced attenuation of
nociceptive behaviors in formalin test
Pre-treatment with SB-334867 (100 mM/0.5 ml, n¼6) antagonized
the effect of 100 nM ORXA (n¼5) induced antinociceptive
behaviors in LPGi (Fig. 4A and B). Intra-LPGi microinjection of
SB-334867 alone (n¼7) produced no effect on phase 1, inter-
phase, and phase 2 in formalin test compared with the LPGi
vehicle-injected rats (1.7870.11: 1.7370.06, P40.05 for phase 1;
1.1070.08: 0.9570.16, P40.05 for inter-phase; 1.8170.08:
1.7470.08, P40.05 for phase 2). SB-334867 was administrated
10 min before ORXA injection.3. Discussion
Orexin-A is produced from the precursor protein prepro-
orexin in neurons which are restricted to a few regions ofthe LH (Peyron et al., 1998; Sakurai et al., 1998). The LH appears
to modify nociception, in part, through the brain stem in
particular the PAG and rostral ventromedial medulla (RVM)
which includes the nucleus raphe magnus (NRM), the adjacent
gigantocellularis pars alpha (NGCa) and LPGi (Behbehani et al.,
1988; Holden and Pizzi, 2008). Moreover, the interaction of LH
with LPGi is documented in several studies (Andrezik et al.,
1981; Li and Lovick, 1985). The injection of orexin-A into the
nuclei of the descending antinociceptive pathway may provide
an opportunity to investigate the role of this neurotransmitter
in the up-down modulating pain system. In our previous study,
the authors investigated the role of midbrain PAG, as a common
substrate in orexin-A antinociception, in formalin and tail flick
tests (Azhdari Zarmehri et al., 2011). We demonstrated that the
microinjection of orexin-A into the PAG reduced the formalin
evoked-nociceptive behaviors in the inter-phase and the late
phase but not the initial phase. Orexin-A failed to produce any
effect on tail flick up to a dose that was effective in formalin
test although the effect of orexin was lower than that observed
with morphine. Recently, Ho et al. (2011) also reported the intra-
PAG microinjection of orexin-A into rats produced analgesic
effect in hot-plat test. The finding that intra-PAG microinjection
of orexin-A has analgesic effect in the rat confirms the PAG to
be an important site of action for orexin-induced supraspinal
antinociception (Azhdari Zarmehri et al., 2011; Ho et al., 2011);
however, it does not rule out the involvement of other suprasp-
inal areas in the orexin-A induced analgesia. There is wide-
spread projections of orexinergic pathway and expression of
orexin receptors in the brain stem including gigantocellularis
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1999; Peyron et al., 1998). In this study, we investigated the role
of LPGi as a common substrate in orexin-A antinociception in
formalin and hot-plate tests.Fig. 3 – Effect on 52 1C hot plate latencies of various doses of
ORXA (A–C columns), at 15 min, 30 min, and 60 min after
intra-paragigantocellularis injection. Values given are
means7S.E.M., and n¼6 in each group. npo0.05; nnpo0.01;
as compared to saline group.
Fig. 4 – Time course of formalin-induced nociceptive beha
(0.5 ll)þORXA (100 nM/0.5 ll) (n¼5), SB-334867 (100 nM/0.5 ll)þv
(100 nM/0.5 l) (n¼6) into the LPGi, measured every 3 min for 60
the LPGi. nPo0.05; nnnPo0.001 in comparison with vehicle groupOur experiments clearly showed that the microinjection of
ORXA into the LPGi has a dose-dependent antinociceptive
effect on acute and tonic phases of formalin test and also
produced an antinociceptive effect on hot-plate test, again in
a dose-dependent manner. Pretreatment with selective OX1R
(SB-334867) partially antagonized the ORXA-induced antino-
ciceptive behaviors after intra-LPGi injection of ORXA, indi-
cating that the antinociceptive effect of ORXA is mediated
through OX1R.
Formalin test is a widely used animal model of unremitting
pain (Abbott et al., 1995; Dubuisson and Dennis, 1977). This
model is used because formalin induces an adequate painful
stimulus leading to spontaneous nociceptive behaviors in
animals. Moreover, formalin as a noxious chemical stimulus,
induces distinct nociceptive behaviors with two distinctive
phases, possibly reflecting the presence of different types of
pain mechanisms in which the spinal or supraspinal pain
modulating networks are involved (Hunskaar et al., 1986;
Hunskaar and Hole, 1987).
Ciriello et al. (2003) have shown that the distribution of
ORXA-labeled axons varies within the specific regions of the
magnocellular reticular area. ORXA axon labeling was
observed mainly within the GiA and LPGi and to lesser extent
within the Gi and RVM (Ciriello et al., 2003). The finding of a
relatively dense ORXA fiber labeling within the GiA and LPGi
is of some interest, as these areas of the brain stem have
previously been demonstrated to play important roles in pain
modulation (Erami et al., 2011; Azami et al., 1982; Heinricher
and Rosenfeld, 1983; Lovick, 1986). However, there are sig-
nificant differences among the sites mediating the ORXA-
induced analgesia in formalin test. As previously reported,
injections of ORXA directly into the GiA and not the LPGi,
elicit a decrease in muscle tone and cardioacceleration
(Ciriello et al., 2003). Therefore, the orexinergic projections
to Gi might be involved in cardioacceleration and muscle
tonicity and that the ORXA terminals in LPGi are critical for
pain modulation (Ciriello et al., 2003).
Since the LH is considered as the exclusive area for ORXA
expression and also implicated as part of a descending
system associated with the modulation of nociceptive trans-
mission in the first synapse in dorsal horn neuron of spinal
cord, thus, it seems that this effect of LH to be mediated inviors score (7S.E.M.) following infusions of the vehicle
ehicle (0.5 ll) (n¼7), and SB-334867 (100 nM/0.5 ll)þORXA
min (A). All microinjections were made into the right side of
.
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et al., 1996). The present findings showed that the ORXA
microinjection into the LPGi produced an antinociceptive
effect on formalin and hot-plate tests, highlighting the
possibility that the origin of the orexinergic inputs to these
structures is involved in top-down pain modulation. The LPGi
nucleus may influence the neurons in dorsal horn of spinal
cord which are involved in both the neurotransmission of
noxious stimuli and modulating the activity of this synapse
as the first gate for ascending nociceptive pathway (Vanegas
and Schaible, 2004; Zhuo and Gebhart, 1997). We suggest that
ORXA might act as a mediator from LH to LPGi to modulate
the pain.
Microinjection of morphine into LPGi produced persistent
and profound analgesia in all phases of formalin test which
was comparable to orexin. This finding is consistent with an
earlier report by Azami et al. (1982) in which morphine was
injected into the LPGi. Akaike et al. (1978) found that the
reticular region consisting the LPGi was 20 times more sensitive
than Gi in demonstrating analgesia by morphine microinjection
and that the electrical stimulation of LPGi caused analgesia
whereas such effect was not present by Gi stimulation. In the
present study, we used formalin test as a pain model different
from those used in previous studies performed on this region
(Akaike et al., 1978; Azami et al., 1982). It seems likely that the
ORXA produces analgesia through activation of a circuit that is
required for opioid analgesia in the LPGi region, an assumption
which needs further studies.
Consistent with other reports on formalin and hot plate tests
(Azhdari Zarmehri et al., 2011; Ho et al., 2011; Yamamoto et al.,
2002), pretreatment with selective OX1R (SB-334867) antago-
nized the antinociceptive behaviors of ORXA in LPGi, indicating
the presence and potential importance of OX1R in the modula-
tion of pain. It has been reported that the selective OX1R
antagonist is pro-hyperalgesic in the mouse carrageenan assay
and therefore, suggesting that during a carrageenan-induced
thermal hyperalgesia test in mice, a tonically activated OX1R
mediated inhibitory system is present (Bingham et al., 2001).
However, SB-334867, at 100 mM concentration alone had no
effect on formalin evoked-behaviors, indicating that a tonic
OX1R mediated inhibitory system does not exist in the LPGi
during the formalin test. This may reflect the presence of strain
differences, route of SB-334867 administration (systemic
against intra-nucleus injection), application of different models
(as seen in hyperalgesia induced by carrageenan and formalin
tests), and also different methodologies (such as stress handling
or anesthesia prior to formalin injection, both known to
influence the test). Our data confirm the previous studies in
which it was revealed that the SB-334867, a selective antagonist
of OX1R, restores the analgesic effect of ORXA after ICV
administration in mice and rats (Bingham et al., 2001;
Yamamoto et al., 2002). Also, it has been suggested that the
antinociceptive effects of ORXA are mediated both via the
spinal and supraspinal mechanisms.4. Conclusion
The present study supports a role for OX1Rs in modulation of
pain caused by LPGi. In addition, the antinociceptive activityof ORXA on formalin-induced behaviors within the LPGi
demonstrated a significant difference. However, the LPGi
was found to be sensitive to antinociceptive effect of ORXA
in both formalin and hot-plate tests.5. Experimental procedures
5.1. Subjects
All experiments involving the study animals were conducted
according to the policy of Iranian Convention for the Protection
of Vertebrate Animals used for Experimental Purposes, and the
protocol was approved by the Ethics Committee of the Medical
School, Qazvin University of Medical Sciences, Qazvin, Iran.
Adult Sprague-Dawley rats (220–300 g) were purchased from
Razi institute (Karaj, Iran). Animals were housed in groups of
three rats per cage and kept at temperature-controlled room,
under a 12 h light–dark cycle with lights on at 7:00–19:00. Food
and water were provided ad libitum. In all experiments, strict
attention was paid to the regulations of local authorities for
handling of laboratory animals.5.2. Surgical preparation for intra-LPGi microinjections
To perform direct intra-LPGi or ICV administrations of drugs
or the respective vehicle (saline), rats were anaesthetized
with Ketamine (100 mg/kg)/ Xylazine (10 mg/kg), placed in a
stereotaxic apparatus (Narishige, Japan). Later, 2 mm holes at
901 angles were drilled in the skull over the LPGi or right
ventricle, and the dura was removed to allow the placement
of a guide cannula. A 23-gauge, 8.6 mm-long stainless steel
guide cannula was stereotaxically (Narishige, Japan) lowered
into the brain at an angle of 901 from the longitudinal axis of
the brain, until the tip was 2 mm above the LPGi by applying
coordinates from the atlas of Paxinos and Watson (2005) with
the bregma serving as the reference for each plane (LPGi; AP,
11.2 –11.8 from bregma; L, 1.5 mm to right; V, 10.6 mm
ventral to the bregma). The cannula was anchored using
dental cement and 2 stainless steel screws in the skull bone.
Immediately after waking up from the surgery, rats were
returned to their home cages to await the formalin test
procedure. One week after the recovery from surgery, rats
were moved to the test room at least an hour before the
commencement of the experiment. Direct intra-nucleus
administration of drugs, or respective vehicle was conducted
with a stainless steel cannula (30 G, 0.3 mm outer diameter)
connected with a polyethylene tube to a Hamilton syringe.
For microinjection procedure, the animal was simply held in
one hand while the microinjection cannula tip was lowered
through the guide cannula (the microinjector tip extended
2 mm below the tip of the guide cannula) and the drug
solutions, or vehicles, in volumes of 0.5 ml, were injected into
the nucleus over a period of 60 s and the injection cannula
was gently removed 1.5 min later. During microinjections,
animals were free to move around the cage with the cannulae
in place. Formalin was injected into the plantar surface of the
right hind paw using a disposable insulin syringe with a fixed
30 G needle.
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The formalin test was performed in a clear plastic box
(303030 cm3) with a mirror placed underneath at 451 angle
to allow an unimpeded view of the animal’s paws. In the
present study, rats were first acclimatized for 30 min in an
acrylic observation chamber followed by injecting 50 ml of 2%
formalin into the plantar surface of the right hind paw with a
30 gauge needle, subcutaneously. To ensure stable scores from
the formalin test, it was necessary to make certain that the
needle was inserted through the skin and run for 5 mm under
the skin. The OX1R antagonist, SB-334867, was given 5 min
before the administration of ORXA, whereas the ORXA was
given 5 min before the formalin test. Following formalin injec-
tion, each rat was immediately returned to the observation box
and the behavioral recording commenced. Pain behaviors were
scored as follows: 0, the injected paw was not favoured; 1, the
injected paw had little or no weight placed on; 2, the injected
paw was elevated and not in contact with any surface; and
3, the injected paw was licked or bit. Recording of the nocicep-
tive behaviors began immediately after the formalin injection
(time 0) and was continued for 60 min. The scores of nocicep-
tive behaviors for each 3 min interval was calculated as the
weighted average of the number of seconds spent on each
nociceptive behavior from the start of the experiment. Scores
were recorded for vehicle injected rats as well as those given
ORXA.
5.4. Hot-plate test
The hot-plate test was used to measure the response latencies
according to the method previously described (Ferreira et al.,
2002; Rhodes and Liebeskind, 1978; Woolfe and MacDonald,
1944) with minor modifications. In these experiments, the
hot-plate (Analgesia meter IITC, Life Science, USA) apparatus
was maintained at 5270.1 1C. The animals, presenting training
latencies higher than 30 s, were excluded. Animals were placed
into an acrylic box (22.522.5 cm2 in diameter) on a heated
surface, and the time (in seconds) between the placement and
licking of their hind paws or jumping (whichever occurred first),
was recorded as the response latency. A 50 s cut-off was used to
prevent tissue damage. Two days before the experiment, all rats
were habituated to the experimental procedure (measurement
of latency) in order to minimize the novelty-induced antinoci-
ception (Siegfried et al., 1987). On the day of experiment, the
animals were injected intra-LPGi with vehicle or drug and
subjected to the hot-plate test 15, 30, and 60 min thereafter.
The dose of orexin-A was selected according to the formalin
test experiments. Different rats were used for formalin test and
hot plate experiments.
5.5. Drugs
Two percent formalin was diluted (Temad, Iran) with sterile
physiological saline solution (Soha, Iran). Orexin-A (MW:
3561, Sigma) and morphine sulfate (Temad Co., Tehran, Iran)
was dissolved in saline, and OX1R antagonist; SB-334867
[N-(2-methyl-6-benzORXA zolyl)-N00-1,5-naphthyridin-4-yl
urea], (MW weight: 356, Tocris), dissolved in dimethyl sulfoxide
(DMSO) and diluted in saline (1:100 in 0.9% w/v salinesolution). All drugs were diluted in saline immediately before
use on the morning of an experiment.
5.6. Histology
At the end of the experiments, rats were deeply anaesthetized
with Ketamine overdose; a volume of 0.5 ml of pontamine sky
blue (%0.2) was also injected into the site 10–20 min before
sacrificing the animals. Rats were then perfused intracardially
with 100 ml of 4% formalin solution and the brain was removed
and sectioned. Only those rats with microinjection site and
diffusion located within the nucleus were included in the results.
In all experiments, ORXA was microinjected into the right LPGi
while the formalin injected into the plantar surface of the right
hind paw (Fig. 1, data from 100 nM orexin-A is shown).
In the formalin test, the percentage of maximum possible
effect (%MPE) was calculated as the percentage difference
between the measured nociceptive behavior during the late
phase (15–60 min) for a group of animals that had been
injected with drug (post-saline) or saline (post-saline). The





Data were presented as mean of 3 min blocks (7S.E.M.) the
total time points of 60 min duration was divided into three
phases marked as phase 1 (from time 0 to minute 7), inter-
phase (from minutes 8 to 14), and phase 2 (from minutes
15 to 60). Data were analyzed by one-way analysis of variance
between the groups. Also, Tukey’s test was employed to
determine whether a significant difference occurred. The
defined level for statistical significance was Po0.05.Acknowledgments
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